HERMES Biosciences, Inc. engages in the development of targeted drug delivery technologies for therapeutic and other biomedical applications. It focuses on integration of technologies of nanosized liposomes and cell-targeting antibody-based ligands into modularly assembled, molecularly targeted, and lipid-based nanocarrier systems for delivering an array of small molecule drugs and probes, macromolecular agents, and nucleic acid therapeutics to target cells.

Company was acquired by Merrimack Pharmaceuticals Inc.